NCT03646188 2026-04-16
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
Phase 1 Terminated
Clinical Trials
58 trialsNCT05814900 2026-04-02
Investigation of Mohs Surgical Margins Using Two Photon Microscopy
University of Rochester
Phase NA Completed
NCT03509467 2025-12-19
Using MC1R Genotype to Impact Melanoma Risk Behavior
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT04916002 2025-12-05
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03816332 2025-10-09
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03897036 2025-05-20
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
Senhwa Biosciences, Inc.
Phase 1 Completed
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT04969419 2025-01-14
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data
Completed
NCT04308395 2024-09-24
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Terminated
NCT00472043 2024-08-06
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Galderma R&D
Phase 3 Completed
NCT00472108 2024-08-05
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Galderma R&D
Phase 3 Completed
NCT04925713 2024-08-02
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
TuHURA Biosciences, Inc.
Phase 1 Completed
NCT03703310 2024-07-03
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Completed
NCT04918381 2023-01-11
CellFX Treat & Resect Low-Risk BCC Feasibility Study
Pulse Biosciences, Inc.
Phase NA Completed
NCT00473343 2023-01-05
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Galderma R&D
Phase 3 Completed
NCT02144077 2022-11-03
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT03541252 2022-04-14
Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
Bispebjerg Hospital
Phase 1/2 Completed
NCT00793169 2021-12-06
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Northwestern University
Completed
NCT02436408 2021-10-28
VISORB
University of Michigan Rogel Cancer Center
Phase 4 Completed
NCT00847912 2021-06-11
VAKCCT
VA Office of Research and Development
Phase 4 Completed
NCT03180528 2021-06-08
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Stanford University
Phase 2 Completed
NCT01556009 2020-11-02
Vismodegib
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT00489086 2020-10-29
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT01245972 2019-09-16
PDLNMSC
University of California, San Diego
Phase NA Completed
NCT02662244 2019-09-06
Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
University of California, San Diego
Phase NA Completed
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT02067104 2019-08-14
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
University of Arizona
Phase 2 Terminated
NCT03237013 2019-07-05
Strategies to Promote Skin Health
San Diego State University
Phase NA Completed
NCT01367665 2019-06-06
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Completed
NCT01700049 2019-05-23
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Mayo Clinic
Phase 2 Completed
NCT02690948 2019-03-08
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Stanford University
Phase 1/2 Completed
NCT02303041 2019-01-29
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT01108094 2018-11-13
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Stanford University
Phase 2 Completed
NCT01791894 2018-06-08
ATO
Stanford University
Phase 1/2 Completed
NCT01631331 2017-12-08
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Stanford University
Phase EARLY_PHASE1 Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT00968981 2017-07-11
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT01898598 2017-05-08
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Terminated
NCT01529450 2017-01-16
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
Stanford University
Phase NA Completed
NCT01508013 2016-06-02
iSTART
East Tennessee State University
Phase NA Completed
NCT00783965 2016-02-11
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT00961896 2015-11-03
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Novartis
Phase 2 Completed
NCT01033019 2015-10-30
To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)
Novartis
Phase 2 Terminated
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed
NCT00833417 2015-05-20
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed